src-2 Antibody

What is SRC-2 and why are antibodies against it important in research?

SRC-2 (Steroid Receptor Coactivator 2) is a critical protein that functions as a transcriptional coactivator. In immunology research, SRC-2 has been identified as an essential regulator of T cell activation and immune tolerance. The protein is known by different designations depending on the research context, including NCOA2 (Nuclear Receptor Coactivator 2) and as an alias for FGR proto-oncogene in some literature. SRC-2 is a 529-amino acid residue protein involved in cell differentiation and innate immune responses, with localization to the cell membrane, mitochondria, and cytoplasm .

Antibodies against SRC-2 are vital research tools because they enable specific detection of this protein in various experimental systems, allowing researchers to investigate its expression, localization, and function in different cell types and disease models. These antibodies support crucial techniques including western blotting, immunohistochemistry, immunoprecipitation, and flow cytometry, facilitating mechanistic studies of SRC-2's role in immune regulation and cellular signaling pathways .

How do I determine the correct SRC-2 antibody for my specific application?

Selecting the appropriate SRC-2 antibody requires consideration of several experimental factors:

• Research application: Different applications require antibodies with specific properties. For western blotting, antibodies that recognize denatured epitopes are necessary, while immunofluorescence requires antibodies that recognize native protein conformations.

• Species compatibility: Verify the antibody's reactivity with your experimental species. Some SRC-2 antibodies are species-specific, while others, like certain polyclonal antibodies, may cross-react across human, mouse, and rat samples .

• Cellular compartment of interest: Since SRC-2 localizes to multiple cellular compartments, choose antibodies validated for detecting SRC-2 in your target location (membrane, cytoplasm, or nucleus).

• Validation data: Review the validation data for the antibody, including western blot images showing detection at the expected molecular weight (approximately 60 kDa for some Src family kinases) .

• Isotype and host species: Consider the antibody isotype and host species to ensure compatibility with secondary detection reagents and to avoid cross-reactivity in multi-color experiments.

Most manufacturers provide detailed application notes and validation data to guide selection. For critical experiments, testing multiple antibodies through small-scale pilot studies is recommended to identify the optimal reagent for your specific experimental system .

What are the optimal protocols for using SRC-2 antibodies in Western blot analysis?

Sample Preparation and Protein Loading:

• Lyse cells in RIPA buffer containing protease and phosphatase inhibitors

• Determine protein concentration using BCA or Bradford assay

• Load 20-40 μg of total protein per lane for cell lysates

• Include positive controls such as MCF-7 human breast cancer cells or A549 human lung carcinoma cells, which express detectable levels of Src

Electrophoresis and Transfer Conditions:

• Use 8-10% SDS-PAGE gels for optimal resolution

• Transfer to PVDF membranes at 100V for 90 minutes in cold transfer buffer

• Verify transfer efficiency with reversible protein stains

Antibody Incubation and Detection:

• Block membranes in 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary SRC-2 antibody at 1 μg/mL concentration (typical dilution 1:1000) overnight at 4°C

• Wash 3-5 times with TBST

• Incubate with appropriate HRP-conjugated secondary antibody (e.g., Anti-Mouse IgG) at recommended dilution

• Wash thoroughly before developing with chemiluminescent substrate

Expected Results:

• SRC family proteins typically detect at approximately 60 kDa

• Include GAPDH (36 kDa) as a loading control

• Perform experiments under reducing conditions using appropriate buffer systems (e.g., Western Blot Buffer Group 1 or Immunoblot Buffer Group 3)

This protocol has been validated using multiple cell lines including MCF-7, Y3-Ag, Rat-2, A549, and HepG2, with U937 and HL-60 serving as potential negative controls for certain SRC family members .

How can I optimize immunofluorescence staining with SRC-2 antibodies?

Fixation and Permeabilization Optimization:

• For membrane-associated SRC-2 detection: Fix cells with 4% paraformaldehyde (10 min), followed by gentle permeabilization with 0.1% Triton X-100 (5 min)

• For cytoplasmic/nuclear SRC-2 detection: Fix with methanol (-20°C, 10 min) for better epitope accessibility

Antigen Retrieval (for tissue sections):

• Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Optimize retrieval times (typically 10-20 minutes) to balance antigen recovery with tissue integrity

Antibody Dilution and Incubation:

• Start with 1:100 dilution in antibody diluent containing 1% BSA

• Optimize concentration through titration experiments (1:50 to 1:500)

• Incubate primary antibody overnight at 4°C in humidity chamber

• Use fluorophore-conjugated secondary antibodies appropriate for your microscopy system

Reducing Background and Increasing Signal:

• Include thorough blocking step with 5-10% normal serum from secondary antibody host species

• Consider signal amplification systems for low-abundance targets

• Include appropriate negative controls (secondary antibody alone, isotype control)

• Counterstain nuclei with DAPI and include cytoskeletal markers for context

Imaging Parameters:

• Capture Z-stacks to ensure complete visualization of subcellular localization

• Use multi-channel acquisition to correlate SRC-2 with other cellular markers

• Employ deconvolution algorithms for improved resolution of subcellular structures

This protocol has been validated on multiple tissue types from rodent and human sources .

What controls should be included when working with SRC-2 antibodies?

A robust experimental design requires the following controls when working with SRC-2 antibodies:

Positive Controls:

• Cell lines with confirmed SRC-2 expression: MCF-7, A549, HepG2, Y3-Ag, and Rat-2 cell lines have been validated for SRC family protein expression

• Tissues with known SRC-2 expression: Neutrophils, monocytes, and natural killer cells show notable expression

• Recombinant SRC-2 protein: Can serve as a positive control in western blot applications

Negative Controls:

• Cell lines with minimal SRC expression: U937 human histiocytic lymphoma and HL-60 human acute promyelocytic leukemia cell lines have been identified as potential negative controls for certain SRC family members

• Isotype controls: Use matched isotype antibodies from the same host species to identify non-specific binding

• Secondary antibody only: Omit primary antibody to detect non-specific secondary antibody binding

Genetic Controls:

• SRC-2 knockout models: Tissues or cells from SRC-2 knockout mice (SRC2^fl/fl/CD4Cre or SRC2^fl/fl/Foxp3YFP-Cre) provide definitive negative controls

• Knockdown validation: siRNA-mediated knockdown of SRC-2 can confirm antibody specificity

Peptide Competition:

• Pre-incubate antibody with immunizing peptide to block specific binding

• Compare staining patterns between blocked and unblocked antibody

Including these controls helps validate antibody specificity, optimize signal-to-noise ratio, and ensure experimental reproducibility across different applications and biological systems .

How can SRC-2 antibodies be used to investigate T cell activation mechanisms?

SRC-2 antibodies are powerful tools for investigating T cell activation mechanisms, as SRC-2 plays a critical role in this process. Research has revealed that SRC-2 functions as a coactivator for c-Myc to stimulate the expression of the amino acid transporter Slc7a5, which is required for T cell activation . Here's how these antibodies can be methodologically employed:

Co-Immunoprecipitation Studies:

• Use SRC-2 antibodies to immunoprecipitate protein complexes from activated T cells

• Perform western blotting for c-Myc and other potential binding partners

• This approach can identify novel protein-protein interactions in the SRC-2 signaling network

Chromatin Immunoprecipitation (ChIP):

• Employ SRC-2 antibodies for ChIP assays to identify genomic binding sites

• Focus on promoter regions of genes involved in T cell activation, particularly Slc7a5

• Combine with sequencing (ChIP-seq) for genome-wide binding profiles

Flow Cytometry:

• Use conjugated SRC-2 antibodies for intracellular staining in conjunction with surface markers of T cell activation

• Correlate SRC-2 expression levels with activation markers like CD25, CD69

• Perform phospho-flow assays to monitor SRC-2-dependent signaling cascades

Functional Assays:

• Compare wild-type and SRC-2-deficient T cells using antibodies to measure:

  • Slc7a5 expression by flow cytometry or western blot

  • c-Myc activation and nuclear translocation

  • Downstream effector activation

Experimental Design Considerations:

• Include time course analyses to capture dynamic changes in SRC-2 expression and localization during T cell activation

• Combine with inhibitors of upstream signaling pathways to establish regulatory hierarchies

• Use SRC-2 antibodies in conjunction with those against phosphorylated forms of signaling intermediates

Research using these approaches has demonstrated that CD4+ T cells from SRC2^fl/fl/CD4Cre mice display defective T cell proliferation, cytokine production, and differentiation both in vitro and in vivo, highlighting the essential role of SRC-2 in T cell activation .

What are the methodological approaches for studying SRC-2's role in autoimmune disease models using specific antibodies?

SRC-2 has been implicated in autoimmune disease regulation, particularly in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. The following methodological approaches can be used to study SRC-2's role in autoimmunity:

In Vivo Disease Model Assessment:

• Use SRC-2 antibodies to monitor protein expression in various immune cell populations isolated from EAE models

• Compare wild-type mice with SRC2^fl/fl/CD4Cre or SRC2^fl/fl/Foxp3YFP-Cre mice, which show resistance to EAE induction

• Track disease progression using clinical scoring, histopathology, and immune cell infiltration analyses

Ex Vivo Analysis of CNS-Infiltrating Cells:

• Isolate central nervous system (CNS) infiltrating lymphocytes from EAE models

• Use SRC-2 antibodies in conjunction with markers for:

  • T cell subsets (CD4, CD8)

  • Cytokine production (IL-17A, IFNγ)

  • Regulatory T cells (Foxp3)

Adoptive Transfer Studies:

• Purify CD4+ T cells from SRC2^fl/fl or SRC2^fl/fl/CD4Cre mice

• Transfer to Rag1^-/- recipients and induce EAE

• Use antibodies to track donor cell localization, proliferation, and function

Mechanistic Studies:

• Investigate SRC-2's interaction with transcription factors like NFAT1

• Examine downstream target gene expression (Nr4a2, Foxp3) using antibodies in western blot or flow cytometry

• Assess amino acid transporter expression (Slc7a5) and function in T cells

Therapeutic Intervention Assessment:

• Test compounds targeting SRC-2 activity in EAE models

• Use antibodies to monitor changes in SRC-2 expression, localization, and activity

• Correlate with clinical outcomes and immune parameters

Research using these approaches has shown that mice deficient in SRC2 in T cells (SRC2^fl/fl/CD4Cre) demonstrate delayed onset and reduced severity of EAE, with greatly reduced infiltration of CD45+ lymphocytes and CD4+ T cells producing IL-17A and IFNγ in the CNS compared to control mice. Additionally, adoptive transfer experiments revealed that CD4+ T cells from SRC2^fl/fl/CD4Cre mice failed to induce EAE in Rag1^-/- recipients, further supporting SRC-2's role in autoimmunity .

How can SRC-2 antibodies be utilized in research on regulatory T cell (Treg) differentiation and function?

SRC-2 plays a crucial role in regulatory T cell (Treg) differentiation and immune tolerance, making SRC-2 antibodies valuable tools for investigating these processes. Based on research findings, here are methodological approaches for utilizing these antibodies:

Treg Differentiation Studies:

• Use SRC-2 antibodies to track protein expression during in vitro Treg differentiation

• Compare naive CD4+ T cells from wild-type versus SRC2^fl/fl/Foxp3YFP-Cre mice during TGF-β-induced differentiation

• Monitor SRC-2 expression kinetics alongside Foxp3 induction to establish temporal relationships

Molecular Mechanism Investigation:

• Perform chromatin immunoprecipitation (ChIP) with SRC-2 antibodies to examine binding to the Nr4a2 promoter

• Combine with NFAT1 ChIP to investigate co-localization at regulatory regions

• Use sequential ChIP (ChIP-reChIP) to confirm simultaneous binding of SRC-2 and NFAT1

Functional Assessment:

• Analyze SRC-2 expression in Tregs using flow cytometry in conjunction with functional markers

• Correlate SRC-2 levels with suppressive capacity in in vitro suppression assays

• Use antibodies to assess SRC-2-dependent Nr4a2 and Foxp3 expression in Tregs

In Vivo Applications:

• Monitor Treg populations in aging SRC2^fl/fl/Foxp3YFP-Cre mice that develop spontaneous autoimmunity

• Examine infiltrating lymphocytes in affected tissues (spleen, lung) for SRC-2 expression

• Correlate with inflammatory cytokine production (IFNγ) and tissue damage

Therapeutic Target Validation:

• Use SRC-2 antibodies to validate target engagement of potential therapeutics

• Monitor changes in SRC-2 expression, localization, or post-translational modifications

• Correlate with functional outcomes in Treg differentiation and suppressive capacity

Research has demonstrated that aged SRC2^fl/fl/Foxp3YFP-Cre mice spontaneously develop autoimmune phenotypes including enlarged spleens, weight loss, and lung inflammation infiltrated with IFNγ-producing CD4+ T cells. These mice also develop more severe EAE due to reduced Tregs. Mechanistically, SRC-2 is recruited by NFAT1 to bind to the Nr4a2 promoter, activating its expression which then stimulates Foxp3 expression to promote Treg differentiation .

What are common technical issues when using SRC-2 antibodies and how can they be resolved?

When facing persistent issues, performing antibody validation experiments is recommended, including testing on known positive and negative controls. SRC-2 knockout or knockdown samples provide definitive controls to establish specificity . Additionally, comparing results across multiple antibodies targeting different epitopes of SRC-2 can help confirm the validity of observed patterns.

How should researchers interpret contradictory results between different SRC-2 antibodies?

When researchers encounter contradictory results between different SRC-2 antibodies, systematic analysis is necessary to determine the cause and establish the most reliable findings:

Epitope Mapping Analysis:

• Determine the exact epitopes recognized by each antibody

• Antibodies targeting different domains of SRC-2 may yield different results due to:

  • Domain-specific protein interactions masking epitopes

  • Post-translational modifications altering epitope accessibility

  • Differential expression of protein isoforms

Antibody Validation Comparison:

• Evaluate validation data for each antibody, including:

  • Western blot profiles showing molecular weight specificity

  • Immunoprecipitation efficiency

  • Knockout/knockdown validation studies

• Prioritize results from antibodies with more extensive validation

Experimental Condition Assessment:

• Compare protocols used with each antibody for differences in:

  • Sample preparation methods (fixation, permeabilization)

  • Blocking agents and times

  • Antibody incubation conditions

  • Detection systems and signal amplification methods

Confirmation with Orthogonal Techniques:

• Validate protein expression using mRNA quantification (qPCR, RNA-seq)

• Utilize tagged protein overexpression systems to confirm localization patterns

• Employ genetic approaches (CRISPR knockouts, siRNA) to validate functional findings

Resolution Strategies for Common Contradictions:

When reporting results, researchers should clearly specify which antibody was used, including catalog number and lot information, to enable proper interpretation and reproducibility. Acknowledging limitations and contradictions in the discussion section of publications is essential for transparency in research .

How are SRC-2 antibodies contributing to our understanding of immune tolerance and autoimmunity?

Recent research utilizing SRC-2 antibodies has significantly advanced our understanding of immune tolerance mechanisms and autoimmune disease pathogenesis. These advances stem from studies examining SRC-2's role in T cell activation and regulatory T cell (Treg) development:

Key Research Contributions:

• T Cell Activation Regulation:
  Research using SRC-2 antibodies has revealed that SRC-2 functions as a coactivator for c-Myc to stimulate expression of the amino acid transporter Slc7a5, which is required for T cell activation. Studies in SRC2^fl/fl/CD4Cre mice demonstrated that SRC-2 deficiency leads to defective T cell proliferation, cytokine production, and differentiation both in vitro and in vivo .

• Experimental Autoimmune Encephalomyelitis (EAE) Models:
  SRC-2 antibodies have helped characterize immune cell populations in EAE models, showing that mice deficient in SRC-2 in T cells (SRC2^fl/fl/CD4Cre) are resistant to EAE induction, with delayed onset and reduced severity. These mice show greatly reduced infiltration of CD45+ lymphocytes and CD4+ T cells producing IL-17A and IFNγ in the central nervous system .

• Treg Differentiation Mechanisms:
  Investigators have used SRC-2 antibodies to demonstrate that SRC-2 stimulates Treg differentiation by activating the Nr4a2 gene. SRC-2 is recruited by NFAT1 to bind to the Nr4a2 promoter, activating its expression which then stimulates Foxp3 expression to promote Treg differentiation .

• Spontaneous Autoimmunity Development:
  Studies show that aged SRC2^fl/fl/Foxp3YFP-Cre mice spontaneously develop autoimmune phenotypes including enlarged spleens, weight loss, and lung inflammation infiltrated with IFNγ-producing CD4+ T cells, highlighting SRC-2's role in maintaining immune homeostasis .

• Infection Susceptibility:
  Research has demonstrated that mice deficient in SRC-2 in T cells are susceptible to Citrobacter rodentium infection, indicating SRC-2's importance in balanced immune responses to pathogens .

Methodological Advances:

• Integration of SRC-2 antibodies in multi-parameter flow cytometry has allowed simultaneous assessment of SRC-2 expression with lineage markers, activation status, and cytokine production

• Development of phospho-specific SRC-2 antibodies has enabled monitoring of SRC-2 activation states during immune responses

• Application of imaging cytometry with SRC-2 antibodies has provided insights into subcellular localization during T cell activation and differentiation

These findings collectively position SRC-2 as a potential therapeutic target for controlling CD4+ T cell-mediated autoimmunity, with antibodies serving as critical tools for target validation and mechanism elucidation .

What emerging applications of SRC-2 antibodies show promise for advancing immunotherapy research?

SRC-2 antibodies are poised to make significant contributions to advancing immunotherapy research, with several emerging applications showing particular promise:

Biomarker Development:

• SRC-2 expression and activation patterns detected by specific antibodies may serve as predictive biomarkers for immunotherapy response

• Flow cytometric analysis of SRC-2 in tumor-infiltrating lymphocytes could help stratify patients for targeted therapies

• Phospho-specific SRC-2 antibodies might identify patients with hyperactive T cell responses prone to cytokine release syndrome

Target Validation for Drug Development:

• SRC-2 antibodies are essential tools for validating SRC-2 as a "druggable" target in autoimmune diseases

• Competitive binding assays using labeled antibodies can screen for small molecule modulators of SRC-2 function

• Proximity ligation assays with SRC-2 antibodies can identify critical protein-protein interactions suitable for therapeutic disruption

CAR-T and Adoptive Cell Therapy Enhancement:

• Monitoring SRC-2 expression using specific antibodies during CAR-T manufacturing may predict cellular product potency

• SRC-2 modulation guided by antibody-based screening could enhance persistence of adoptively transferred T cells

• Antibody-based sorting of T cells with optimal SRC-2 expression profiles might improve therapeutic efficacy

Combination Therapy Approaches:

• SRC-2 antibodies can help identify rational combinations of immunomodulatory agents by monitoring pathway activity

• Characterization of SRC-2 status in checkpoint inhibitor resistance might reveal new therapeutic targets

• Imaging with labeled SRC-2 antibodies could track therapy-induced changes in immune cell activation in vivo

Emerging Research Directions:

• Development of humanized models expressing human SRC-2 variants to better translate findings to clinical applications

• Creation of site-specific SRC-2 phospho-antibodies to map activation signals during different immune responses

• Integration of SRC-2 antibodies into high-dimensional analyses (mass cytometry, spatial proteomics) to contextualize its role in the immune microenvironment

The significance of these applications is underscored by research demonstrating SRC-2's pivotal role in controlling the scale of immune responses through mechanisms like the activation of Nr4a2 gene to promote CD4+Foxp3+ induced Treg differentiation . As immune dysregulation underlies many diseases beyond classical autoimmunity, these emerging applications of SRC-2 antibodies may have broad clinical relevance in cancer immunotherapy, transplant medicine, and inflammatory disorders.

What are the best practices for incorporating SRC-2 antibodies in multiparameter research designs?

Incorporating SRC-2 antibodies into multiparameter research designs requires careful planning and optimization to generate reliable, comprehensive data. Here are best practices based on current research methodologies:

Experimental Design Optimization:

• Begin with power analysis to determine appropriate sample sizes and replication strategy

• Include hierarchical validation steps, starting with antibody specificity verification in simple systems before moving to complex multiparameter analyses

• Design experiments with appropriate controls for each parameter being measured alongside SRC-2

• Consider factorial experimental designs to efficiently evaluate multiple variables affecting SRC-2 function

Panel Design for Multi-Parameter Flow Cytometry:

• Place SRC-2 antibodies in channels with sufficient separation from potentially cross-talking fluorophores

• Include critical lineage markers (CD4, CD8, CD3) and functional markers (activation, exhaustion, cytokines) alongside SRC-2

• Optimize fixation and permeabilization protocols to balance surface marker preservation with intracellular SRC-2 detection

• Validate compensation using single-stained controls for each parameter in your panel

Integrating with Functional Assays:

• Correlate SRC-2 expression with functional readouts (proliferation, cytokine production, killing capacity)

• Design time-course experiments to capture dynamic changes in SRC-2 expression/activation during immune responses

• Incorporate transcriptional analysis (RNA-seq, qPCR) to link SRC-2 protein levels with downstream gene expression

• Consider assessing SRC-2 binding partners through complementary co-immunoprecipitation experiments

Data Analysis Strategies:

• Employ dimensionality reduction techniques (tSNE, UMAP) for visualizing SRC-2 expression across heterogeneous cell populations

• Use clustering algorithms to identify cell subsets with distinct SRC-2 expression patterns

• Implement machine learning approaches to identify complex relationships between SRC-2 and other measured parameters

• Validate computational findings with targeted follow-up experiments

Quality Control Measures:

• Include fluorescence-minus-one (FMO) controls for accurate gating of SRC-2 positive populations

• Run antibody titration experiments to determine optimal signal-to-noise ratios

• Maintain consistent instrument settings across experiments using calibration beads

• Document batch effects and account for them in statistical analyses

Research has demonstrated the value of these approaches in characterizing SRC-2's role in T cell activation through c-Myc coactivation and in Treg differentiation via Nr4a2 regulation , highlighting the importance of multiparameter analysis in elucidating complex immunological mechanisms.

What should researchers consider when planning long-term research programs involving SRC-2 antibodies?

Researchers planning long-term research programs involving SRC-2 antibodies should consider several strategic and practical factors to ensure continuity, reproducibility, and maximal scientific impact:

Antibody Supply and Consistency:

• Purchase larger antibody lots when possible and aliquot to minimize freeze-thaw cycles

• Establish relationships with reliable suppliers with consistent manufacturing processes

• Consider developing in-house monoclonal antibodies for critical applications to ensure long-term supply

• Maintain detailed records of antibody performance across lots for early detection of manufacturing changes

Technology Evolution Planning:

• Design initial experiments with samples that can be revisited with emerging technologies

• Establish biobanking protocols for preserving specimens compatible with future analytical methods

• Invest in learning complementary technologies (CyTOF, imaging mass cytometry, spatial transcriptomics) that may enhance SRC-2 research

• Develop computational pipelines that can accommodate data from evolving methodologies

Collaborative Infrastructure Development:

• Establish core facilities or shared resources for specialized SRC-2 analyses

• Create standardized protocols for SRC-2 detection that can be shared across research groups

• Develop shared animal models (SRC2^fl/fl crossed with various tissue-specific Cre lines) for consistent in vivo studies

• Implement data sharing platforms to accelerate discovery through multi-institutional collaboration

Translational Pathway Considerations:

• Incorporate clinically relevant models early in research programs to facilitate eventual translation

• Develop and validate SRC-2 assays that could be adapted for clinical samples

• Consider regulatory requirements for companion diagnostics if SRC-2 becomes a therapeutic target

• Establish bioethical frameworks for patient-derived sample collection and analysis

Funding and Resource Allocation Strategy:

• Diversify funding sources to ensure program continuity through fluctuations in specific grant mechanisms

• Allocate resources for technology development alongside hypothesis-driven research

• Budget for regular antibody validation and quality control throughout the program lifecycle

• Invest in training personnel in specialized techniques for SRC-2 detection and analysis

Long-term Research Questions to Consider:

• How does SRC-2 function change throughout the lifespan and in aging-associated immune dysfunction?

• What is the relationship between SRC-2 and other SRC family members in regulating immune homeostasis?

• How do environmental factors and exposures modulate SRC-2 activity in immune cells?

• Can SRC-2-targeted therapies be developed with acceptable safety profiles for autoimmune diseases?